Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in Helicobacter pylori vaccination.

J G Kusters1

  • 1Dept. of Gastroenterology and Hepatology, Dijkzigt Hospital, Rotterdam, The Netherlands. Kusters@MDL.AZR.NL

Scandinavian Journal of Gastroenterology. Supplement
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multidrug-resistant Mycoplasma genitalium infections in Europe.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2017
Same author

Raman spectroscopy-based identification of nosocomial outbreaks of the clonal bacterium Escherichia coli.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2015
Same author

High prevalence of azole resistance in Aspergillus fumigatus isolates from high-risk patients.

The Journal of antimicrobial chemotherapy·2015
Same author

A multiplex real-time PCR assay for routine diagnosis of bacterial vaginosis.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2015
Same author

High levels of macrolide resistance-associated mutations in Mycoplasma genitalium warrant antibiotic susceptibility-guided treatment.

The Journal of antimicrobial chemotherapy·2015
Same author

Increased prevalence of gastrointestinal viruses and diminished secretory immunoglobulin a levels in antibody deficiencies.

Journal of clinical immunology·2014

Developing a vaccine against Helicobacter pylori infection is crucial due to antibiotic resistance. Research indicates a Th2-type immune response is needed for protection, though challenges remain for clinical application.

Area of Science:

  • Microbiology
  • Immunology
  • Vaccinology

Background:

  • Helicobacter pylori is a common gram-negative bacterium causing chronic gastritis, peptic ulcers, and gastric cancers.
  • Current antimicrobial therapies for H. pylori infection face challenges including resistance, side effects, and cost.
  • Vaccines offer a promising alternative for H. pylori prevention and eradication due to their efficacy and cost-effectiveness.

Purpose of the Study:

  • To review recent advancements in the development of a vaccine against Helicobacter pylori.
  • To highlight the immunological responses required for protective immunity against H. pylori.
  • To identify key challenges hindering the clinical translation of H. pylori vaccines.

Main Methods:

  • Review of current scientific literature on Helicobacter pylori vaccines.

Related Experiment Videos

  • Analysis of immune responses (Th1 vs. Th2) associated with natural infection and vaccination.
  • Evaluation of progress in vaccine development and remaining obstacles.

    • Main Results:

    • Natural H. pylori infection elicits a Th1 response, which is not protective.
    • Vaccination studies suggest a Th2-type response is necessary for protection, but mechanisms are not fully understood.
    • Commercial development is progressing, but issues like mucosal adjuvants and side effects require resolution.

    Conclusions:

    • Vaccines represent a viable strategy for controlling H. pylori infections.
    • Further research is needed to understand protective immune mechanisms and address safety concerns for vaccine development.
    • Overcoming challenges in adjuvant selection and side effect prevention is critical for successful H. pylori vaccine deployment.